Protection against Staphylococcus aureus and tetanus infections by a combined vaccine containing SasA and TeNT‑Hc in mice

Yang,Yilong; Yu,Rui; Yang,Xiuxu; Liu,Shuling; Fang,Ting; Song,Xiaohong; Hou,Lihua; Yu,Changming; Xu,Junjie; Fu,Ling; Yi,Shaoqiong; Chen,Wei

doi:10.3892/mmr.2017.6227

Protection against Staphylococcus aureus and tetanus infections by a combined vaccine containing SasA and TeNT‑Hc in mice

Authors:
- Yilong Yang
- Rui Yu
- Xiuxu Yang
- Shuling Liu
- Ting Fang
- Xiaohong Song
- Lihua Hou
- Changming Yu
- Junjie Xu
- Ling Fu
- Shaoqiong Yi
- Wei Chen
View Affiliations

Affiliations: Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Fengtai, Beijing 100071, P.R. China
Published online on: February 21, 2017 https://doi.org/10.3892/mmr.2017.6227
Pages: 2369-2373

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In developing countries, trauma patients and neonates are vulnerable to Staphylococcus aureus (S. aureus) and Clostridium tetani infections. It has been suggested that a combined vaccine against the two infections may be a reliable and cost‑effective strategy. Previous studies have indicated that the S. aureus surface protein A (SasA) and the C fragment of tetanus neurotoxin (TeNT‑Hc) may be suitable candidates for a vaccine against S. aureus and tetanus infections, respectively. In the present study, mice were immunized with a combined vaccine containing SasA and TeNT‑Hc, which induced a robust immune response to both antigens, and mutual interference between SasA and TeNT‑Hc was not observed. In the S.aureus challenge model, the combined vaccine fully protected BALB/c mice against lethal intraperitoneal challenges with 3x109 colony‑forming units of a methicillin‑resistant S. aureus USA300 strain. In the TeNT challenge model, the combined vaccine conferred complete protection against a lethal dose of (2x103) xLD50 tetanus toxin. These results implied that SasA and TeNT‑Hc promising components for a combined vaccine against S. aureus and tetanus infections.

View Figures

View References

1	Zhang B, Liu Z, Lin Z, Zhang X and Fu W: Microbiologic characteristics of pathogenic bacteria from hospitalized trauma patients who survived Wenchuan earthquake. Eur J Clin Microbiol Infect Dis. 31:2529–2535. 2012. View Article : Google Scholar : PubMed/NCBI
2	Afshar M, Raju M, Ansell D and Bleck TP: Narrative review: Tetanus-a health threat after natural disasters in developing countries. Ann Intern Med. 154:329–335. 2011. View Article : Google Scholar : PubMed/NCBI
3	Udo JJ, Anah MU, Ochigbo SO, Etuk IS and Ekanem AD: Neonatal morbidity and mortality in Calabar, Nigeria: A hospital-based study. Niger J Clin Pract. 11:285–289. 2008.PubMed/NCBI
4	Peacock SJ, de Silva I and Lowy FD: What determines nasal carriage of Staphylococcus aureus? Trends Microbiol. 9:605–610. 2001. View Article : Google Scholar : PubMed/NCBI
5	Lowy FD: Staphylococcus aureus infections. N Engl J Med. 339:520–532. 1998. View Article : Google Scholar : PubMed/NCBI
6	Chalya PL, Mabula JB, Dass RM, Mbelenge N, Mshana SE and Gilyoma JM: Ten-year experiences with Tetanus at a Tertiary hospital in Northwestern Tanzania: A retrospective review of 102 cases. World J Emerg Surg. 6:202011. View Article : Google Scholar : PubMed/NCBI
7	World Health Organization, . Immunization, vaccines and biologicals: Tetanus. http://www.who.int/immunization/diseases/teta-nus/enNovember 3–2016.
8	Skibinski DA, Baudner BC, Singh M and O'Hagan DT: Combination vaccines. J Glob Infect Dis. 3:63–72. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yi SQ, Zhang XY, Yang YL, Yang Y, Liu SL, Fu L, Yu CM and Chen W: Immunity induced by Staphylococcus aureus surface protein A was protective against lethal challenge of Staphylococcus aureus in BALB/c mice. Microbiol Immunol. 56:406–410. 2012. View Article : Google Scholar : PubMed/NCBI
10	Siboo IR, Chambers HF and Sullam PM: Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets. Infect Immun. 73:2273–2280. 2005. View Article : Google Scholar : PubMed/NCBI
11	Roche FM, Massey R, Peacock SJ, Day NP, Visai L, Speziale P, Lam A, Pallen M and Foster TJ: Characterization of novel LPXTG-containing proteins of Staphylococcus aureus identified from genome sequences. Microbiology. 149:643–654. 2003. View Article : Google Scholar : PubMed/NCBI
12	Montecucco C and Schiavo G: Tetanus and botulism neurotoxins: A new group of zinc proteases. Trends Biochem Sci. 18:324–327. 1993. View Article : Google Scholar : PubMed/NCBI
13	Schiavo G, Benfenati F, Poulain B, Rossetto O, De Laureto P Polverino, DasGupta BR and Montecucco C: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 359:832–835. 1992. View Article : Google Scholar : PubMed/NCBI
14	Sinha K, Box M, Lalli G, Schiavo G, Schneider H, Groves M, Siligardi G and Fairweather N: Analysis of mutants of tetanus toxin Hc fragment: Ganglioside binding, cell binding and retrograde axonal transport properties. Mol Microbiol. 37:1041–1051. 2000. View Article : Google Scholar : PubMed/NCBI
15	Yu R, Yi S, Yu C, Fang T, Liu S, Yu T, Song X, Fu L, Hou L and Chen W: A conformational change of C fragment of tetanus neurotoxin reduces its ganglioside-binding activity but does not destroy its immunogenicity. Clin Vaccine Immunol. 18:1668–1672. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yu R, Hou L, Yu C, Liu S, Ren J, Fang T, Zhang X and Chen W: Enhanced expression of soluble recombinant tetanus neurotoxin Hc in Escherichia coli for use as a tetanus vaccine candidate. Immunobiology. 216:485–490. 2011. View Article : Google Scholar : PubMed/NCBI
17	Rauch S, DeDent AC, Kim HK, Wardenburg J Bubeck, Missiakas DM and Schneewind O: Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection. Infect Immun. 80:3721–3732. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ulrich R and Miller J: Threshold estimation in two-alternative forced-choice (2AFC) tasks: The Spearman-Kärber method. Percept Psychophys. 66:517–533. 2004. View Article : Google Scholar : PubMed/NCBI
19	Booy R, Aitken SJ, Taylor S, Tudor-Williams G, Macfarlane JA, Moxon ER, Ashworth LA, Mayon-White RT, Griffiths H and Chapel HM: Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3 and 4 months versus 3, 5 and 9 months of age. Lancet. 339:507–510. 1992. View Article : Google Scholar : PubMed/NCBI
20	West DJ, Rabalais GP, Watson B, Keyserling HL, Matthews H and Hesley TM: Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines. BioDrugs. 15:413–418. 2001. View Article : Google Scholar : PubMed/NCBI
21	Joines RW, Blatter M, Abraham B, Xie F, De Clercq N, Baine Y, Reisinger KS, Kuhnen A and Parenti DL: A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine. 19:4710–4719. 2001. View Article : Google Scholar : PubMed/NCBI
22	Ortqvist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, Lindblad I, Sundelöf B and Kalin M: Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 351:399–403. 1998. View Article : Google Scholar : PubMed/NCBI
23	Robbins JB, Schneerson R, Horwith G, Naso R and Fattom A: Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am Heart J. 147:593–598. 2004. View Article : Google Scholar : PubMed/NCBI
24	Maira-Litran T, Kropec A, Goldmann D and Pier GB: Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide. Vaccine. 22:872–879. 2004. View Article : Google Scholar : PubMed/NCBI
25	Joshi A, Pancari G, Cope L, Bowman EP, Cua D, Proctor RA and McNeely T: Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother. 8:336–346. 2012. View Article : Google Scholar : PubMed/NCBI
26	Josefsson E, Hartford O, O'Brien L, Patti JM and Foster T: Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis. 184:1572–1580. 2001. View Article : Google Scholar : PubMed/NCBI
27	Schaffer AC, Solinga RM, Cocchiaro J, Portoles M, Kiser KB, Risley A, Randall SM, Valtulina V, Speziale P, Walsh E, et al: Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun. 74:2145–2153. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kim HK, Cheng AG, Kim HY, Missiakas DM and Schneewind O: Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med. 207:1863–1870. 2010. View Article : Google Scholar : PubMed/NCBI
29	Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC and Lowy FD: Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis. 198:571–575. 2008. View Article : Google Scholar : PubMed/NCBI
30	Nilsson IM, Patti JM, Bremell T, Höök M and Tarkowski A: Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest. 101:2640–2649. 1998. View Article : Google Scholar : PubMed/NCBI
31	Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM and Schneewind O: Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog. 6:e10010362010. View Article : Google Scholar : PubMed/NCBI
32	Wardenburg J Bubeck and Schneewind O: Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med. 205:287–294. 2008. View Article : Google Scholar : PubMed/NCBI
33	Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, Vazquez V, Etienne J, Lina G, Vandenesch F and Bowden MG: The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect. 15:156–164. 2009. View Article : Google Scholar :
34	Hu DL, Omoe K, Narita K, Cui JC, Shinagawa K and Nakane A: Intranasal vaccination with a double mutant of staphylococcal enterotoxin C provides protection against Staphylococcus aureus infection. Microbes Infect. 8:2841–2848. 2006. View Article : Google Scholar : PubMed/NCBI
35	Hu DL, Omoe K, Sasaki S, Sashinami H, Sakuraba H, Yokomizo Y, Shinagawa K and Nakane A: Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis. 188:743–752. 2003. View Article : Google Scholar : PubMed/NCBI
36	Bagnoli F, Bertholet S and Grandi G: Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol. 2:162012. View Article : Google Scholar : PubMed/NCBI
37	Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, et al: Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet. 367:731–739. 2006. View Article : Google Scholar : PubMed/NCBI
38	Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J, Wasserman SS, Edelman R, Chatfield S, Dougan G and Levine MM: Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol. 97:146–153. 2000. View Article : Google Scholar : PubMed/NCBI
39	Lee S, Belitsky BR, Brown DW, Brinker JP, Kerstein KO, Herrmann JE, Keusch GT, Sonenshein AL and Tzipori S: Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine. 28:6658–6665. 2010. View Article : Google Scholar : PubMed/NCBI
40	Bongat AF, Saksena R, Adamo R, Fujimoto Y, Shiokawa Z, Peterson DC, Fukase K, Vann WF and Kovác P: Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant. Glycoconj J. 27:69–77. 2010. View Article : Google Scholar : PubMed/NCBI
41	Salgado-Pabón W and Schlievert PM: Models matter: The search for an effective Staphylococcus aureus vaccine. Nat Rev Microbiol. 12:585–591. 2014. View Article : Google Scholar : PubMed/NCBI
42	Stranger-Jones YK, Bae T and Schneewind O: Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA. 103:16942–16947. 2006. View Article : Google Scholar : PubMed/NCBI